Industrial - Machinery
Compare Stocks
5 / 10Stock Comparison
HLIO vs CAT vs EMR vs ETN vs HON
Revenue, margins, valuation, and 5-year total return — side by side.
Agricultural - Machinery
Industrial - Machinery
Industrial - Machinery
Conglomerates
HLIO vs CAT vs EMR vs ETN vs HON — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | |||||
|---|---|---|---|---|---|
| Industry | Industrial - Machinery | Agricultural - Machinery | Industrial - Machinery | Industrial - Machinery | Conglomerates |
| Market Cap | $2.25B | $416.75B | $79.02B | $155.02B | $136.91B |
| Revenue (TTM) | $839M | $70.75B | $18.32B | $28.52B | $36.76B |
| Net Income (TTM) | $49M | $9.42B | $2.44B | $3.99B | $4.10B |
| Gross Margin | 32.3% | 32.5% | 52.7% | 36.9% | 36.9% |
| Operating Margin | 7.8% | 16.6% | 19.8% | 18.1% | 14.9% |
| Forward P/E | 26.9x | 38.8x | 21.7x | 30.0x | 20.5x |
| Total Debt | $111M | $43.33B | $13.76B | $11.17B | $34.58B |
| Cash & Equiv. | $73M | $9.98B | $1.54B | $622M | $12.49B |
HLIO vs CAT vs EMR vs ETN vs HON — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
| Stock | May 20 | May 26 | Return |
|---|---|---|---|
| Helios Technologies… (HLIO) | 100 | 190.1 | +90.1% |
| Caterpillar Inc. (CAT) | 100 | 745.6 | +645.6% |
| Emerson Electric Co. (EMR) | 100 | 231.2 | +131.2% |
| Eaton Corporation p… (ETN) | 100 | 470.2 | +370.2% |
| Honeywell Internati… (HON) | 100 | 148.1 | +48.1% |
Price return only. Dividends and distributions are not included.
Quick Verdict: HLIO vs CAT vs EMR vs ETN vs HON
Each card shows where this stock fits in a portfolio — not just who wins on paper.
HLIO is the clearest fit if your priority is valuation efficiency.
- PEG 1.00 vs HON's 11.18
- Lower P/E (26.9x vs 30.0x), PEG 1.00 vs 1.22
CAT has the current edge in this matchup, primarily because of its strength in long-term compounding.
- 12.3% 10Y total return vs ETN's 6.1%
- +181.5% vs HON's +2.8%
- 10.0% ROA vs HLIO's 3.1%, ROIC 15.9% vs 4.4%
Among these 5 stocks, EMR doesn't own a clear edge in any measured category.
ETN is the #2 pick in this set and the best alternative if growth exposure and sleep-well-at-night is your priority.
- Rev growth 10.3%, EPS growth 10.1%, 3Y rev CAGR 9.8%
- Lower volatility, beta 1.42, Low D/E 57.4%, current ratio 1.32x
- 10.3% revenue growth vs EMR's 3.0%
- 14.0% margin vs HLIO's 5.8%
HON ranks third and is worth considering specifically for income & stability and defensive.
- Dividend streak 15 yrs, beta 0.74, yield 2.1%
- Beta 0.74, yield 2.1%, current ratio 1.32x
- Beta 0.74 vs HLIO's 1.56
- 2.1% yield, 15-year raise streak, vs EMR's 1.5%
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | 10.3% revenue growth vs EMR's 3.0% | |
| Value | Lower P/E (26.9x vs 30.0x), PEG 1.00 vs 1.22 | |
| Quality / Margins | 14.0% margin vs HLIO's 5.8% | |
| Stability / Safety | Beta 0.74 vs HLIO's 1.56 | |
| Dividends | 2.1% yield, 15-year raise streak, vs EMR's 1.5% | |
| Momentum (1Y) | +181.5% vs HON's +2.8% | |
| Efficiency (ROA) | 10.0% ROA vs HLIO's 3.1%, ROIC 15.9% vs 4.4% |
HLIO vs CAT vs EMR vs ETN vs HON — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
HLIO vs CAT vs EMR vs ETN vs HON — Financial Metrics
Side-by-side numbers across 5 stocks — who leads on profitability, valuation, growth, and risk.
Who Leads Where
EMR leads in 1 of 6 categories
HLIO leads 1 • CAT leads 1 • ETN leads 0 • HON leads 0 • 3 tied
Explore the data ↓Income & Cash Flow (Last 12 Months)
EMR leads this category, winning 3 of 6 comparable metrics.
Income & Cash Flow (Last 12 Months)
CAT is the larger business by revenue, generating $70.8B annually — 84.3x HLIO's $839M. ETN is the more profitable business, keeping 14.0% of every revenue dollar as net income compared to HLIO's 5.8%. On growth, CAT holds the edge at +22.2% YoY revenue growth, suggesting stronger near-term business momentum.
| Metric | |||||
|---|---|---|---|---|---|
| RevenueTrailing 12 months | $839M | $70.8B | $18.3B | $28.5B | $36.8B |
| EBITDAEarnings before interest/tax | $129M | $14.0B | $4.7B | $5.9B | $6.5B |
| Net IncomeAfter-tax profit | $49M | $9.4B | $2.4B | $4.0B | $4.1B |
| Free Cash FlowCash after capex | $103M | $11.4B | $3.1B | $4.7B | $4.2B |
| Gross MarginGross profit ÷ Revenue | +32.3% | +32.5% | +52.7% | +36.9% | +36.9% |
| Operating MarginEBIT ÷ Revenue | +7.8% | +16.6% | +19.8% | +18.1% | +14.9% |
| Net MarginNet income ÷ Revenue | +5.8% | +13.3% | +13.3% | +14.0% | +11.2% |
| FCF MarginFCF ÷ Revenue | +12.3% | +16.2% | +17.0% | +16.5% | +11.4% |
| Rev. Growth (YoY)Latest quarter vs prior year | +17.4% | +22.2% | +2.9% | +16.8% | -6.9% |
| EPS Growth (YoY)Latest quarter vs prior year | +3.1% | +30.2% | +28.2% | -9.4% | -41.9% |
Valuation Metrics
HLIO leads this category, winning 4 of 7 comparable metrics.
Valuation Metrics
At 29.4x trailing earnings, HON trades at a 38% valuation discount to CAT's 47.6x P/E. Adjusting for growth (PEG ratio), ETN offers better value at 1.55x vs HON's 15.99x — a lower PEG means you pay less per unit of expected earnings growth.
| Metric | |||||
|---|---|---|---|---|---|
| Market CapShares × price | $2.3B | $416.8B | $79.0B | $155.0B | $136.9B |
| Enterprise ValueMkt cap + debt − cash | $2.3B | $450.1B | $91.2B | $165.6B | $159.0B |
| Trailing P/EPrice ÷ TTM EPS | 46.89x | 47.57x | 34.92x | 38.17x | 29.36x |
| Forward P/EPrice ÷ next-FY EPS est. | 26.92x | 38.79x | 21.71x | 30.00x | 20.52x |
| PEG RatioP/E ÷ EPS growth rate | 1.74x | 1.69x | 7.73x | 1.55x | 15.99x |
| EV / EBITDAEnterprise value multiple | 17.74x | 33.41x | 18.07x | 27.69x | 19.99x |
| Price / SalesMarket cap ÷ Revenue | 2.68x | 6.17x | 4.39x | 5.65x | 3.66x |
| Price / BookPrice ÷ Book value/share | 2.43x | 19.71x | 3.94x | 7.99x | 9.00x |
| Price / FCFMarket cap ÷ FCF | 21.72x | 40.56x | 29.63x | 34.67x | 25.39x |
Profitability & Efficiency
Evenly matched — HLIO and CAT each lead in 4 of 9 comparable metrics.
Profitability & Efficiency
CAT delivers a 47.5% return on equity — every $100 of shareholder capital generates $48 in annual profit, vs $5 for HLIO. HLIO carries lower financial leverage with a 0.12x debt-to-equity ratio, signaling a more conservative balance sheet compared to HON's 2.24x. On the Piotroski fundamental quality scale (0–9), HLIO scores 9/9 vs CAT's 5/9, reflecting strong financial health.
| Metric | |||||
|---|---|---|---|---|---|
| ROE (TTM)Return on equity | +5.3% | +47.5% | +12.1% | +20.8% | +23.1% |
| ROA (TTM)Return on assets | +3.1% | +10.0% | +5.8% | +9.0% | +5.3% |
| ROICReturn on invested capital | +4.4% | +15.9% | +8.2% | +13.6% | +12.6% |
| ROCEReturn on capital employed | +4.8% | +19.1% | +10.0% | +16.8% | +12.6% |
| Piotroski ScoreFundamental quality 0–9 | 9 | 5 | 7 | 6 | 6 |
| Debt / EquityFinancial leverage | 0.12x | 2.03x | 0.68x | 0.57x | 2.24x |
| Net DebtTotal debt minus cash | $38M | $33.4B | $12.2B | $10.5B | $22.1B |
| Cash & Equiv.Liquid assets | $73M | $10.0B | $1.5B | $622M | $12.5B |
| Total DebtShort + long-term debt | $111M | $43.3B | $13.8B | $11.2B | $34.6B |
| Interest CoverageEBIT ÷ Interest expense | 3.84x | 9.22x | 6.46x | 16.38x | 3.92x |
Total Returns (Dividends Reinvested)
CAT leads this category, winning 6 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in CAT five years ago would be worth $38,251 today (with dividends reinvested), compared to $9,193 for HLIO. Over the past 12 months, CAT leads with a +181.5% total return vs HON's +2.8%. The 3-year compound annual growth rate (CAGR) favors CAT at 62.0% vs HLIO's 3.6% — a key indicator of consistent wealth creation.
| Metric | |||||
|---|---|---|---|---|---|
| YTD ReturnYear-to-date | +24.7% | +50.2% | +4.3% | +22.3% | +10.9% |
| 1-Year ReturnPast 12 months | +134.6% | +181.5% | +30.4% | +33.2% | +2.8% |
| 3-Year ReturnCumulative with dividends | +11.1% | +324.9% | +75.9% | +141.3% | +16.2% |
| 5-Year ReturnCumulative with dividends | -8.1% | +282.5% | +59.5% | +182.8% | +3.3% |
| 10-Year ReturnCumulative with dividends | +109.8% | +1227.6% | +206.6% | +608.7% | +135.1% |
| CAGR (3Y)Annualised 3-year return | +3.6% | +62.0% | +20.7% | +34.1% | +5.1% |
Risk & Volatility
Evenly matched — CAT and HON each lead in 1 of 2 comparable metrics.
Risk & Volatility
HON is the less volatile stock with a 0.74 beta — it tends to amplify market swings less than HLIO's 1.56 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. CAT currently trades 96.2% from its 52-week high vs EMR's 85.4% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | |||||
|---|---|---|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 1.56x | 1.54x | 1.52x | 1.42x | 0.74x |
| 52-Week HighHighest price in past year | $76.47 | $931.35 | $165.15 | $435.43 | $248.18 |
| 52-Week LowLowest price in past year | $28.34 | $318.11 | $108.37 | $296.93 | $186.76 |
| % of 52W HighCurrent price vs 52-week peak | +88.9% | +96.2% | +85.4% | +91.7% | +87.1% |
| RSI (14)Momentum oscillator 0–100 | 55.2 | 76.2 | 61.3 | 59.8 | 45.1 |
| Avg Volume (50D)Average daily shares traded | 350K | 2.4M | 2.8M | 2.5M | 3.7M |
Analyst Outlook
Evenly matched — EMR and HON each lead in 1 of 2 comparable metrics.
Analyst Outlook
Analyst consensus: HLIO as "Buy", CAT as "Buy", EMR as "Buy", ETN as "Buy", HON as "Buy". Consensus price targets imply 14.8% upside for EMR (target: $162) vs -7.9% for CAT (target: $825). For income investors, HON offers the higher dividend yield at 2.14% vs HLIO's 0.53%.
| Metric | |||||
|---|---|---|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Buy | Buy | Buy | Buy | Buy |
| Price TargetConsensus 12-month target | $77.00 | $824.80 | $161.92 | $379.78 | $243.83 |
| # AnalystsCovering analysts | 12 | 53 | 41 | 39 | 28 |
| Dividend YieldAnnual dividend ÷ price | +0.5% | +0.7% | +1.5% | +1.0% | +2.1% |
| Dividend StreakConsecutive years of raises | 1 | 8 | 37 | 24 | 15 |
| Dividend / ShareAnnual DPS | $0.36 | $5.86 | $2.10 | $4.17 | $4.63 |
| Buyback YieldShare repurchases ÷ mkt cap | +0.6% | +1.2% | +1.6% | +1.2% | +2.8% |
EMR leads in 1 of 6 categories (Income & Cash Flow). HLIO leads in 1 (Valuation Metrics). 3 tied.
HLIO vs CAT vs EMR vs ETN vs HON: Key Questions Answered
10 questions · data-driven answers · updated daily
01Is HLIO or CAT or EMR or ETN or HON a better buy right now?
For growth investors, Eaton Corporation plc (ETN) is the stronger pick with 10.
3% revenue growth year-over-year, versus 3. 0% for Emerson Electric Co. (EMR). Honeywell International Inc. (HON) offers the better valuation at 29. 4x trailing P/E (20. 5x forward), making it the more compelling value choice. Analysts rate Helios Technologies, Inc. (HLIO) a "Buy" — based on 12 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which has the better valuation — HLIO or CAT or EMR or ETN or HON?
On trailing P/E, Honeywell International Inc.
(HON) is the cheapest at 29. 4x versus Caterpillar Inc. at 47. 6x. On forward P/E, Honeywell International Inc. is actually cheaper at 20. 5x. The PEG ratio (P/E divided by earnings growth rate) is the most growth-adjusted single valuation metric: Helios Technologies, Inc. wins at 1. 00x versus Honeywell International Inc. 's 11. 18x — a PEG below 1. 0 traditionally signals the market is underpricing earnings growth.
03Which is the better long-term investment — HLIO or CAT or EMR or ETN or HON?
Over the past 5 years, Caterpillar Inc.
(CAT) delivered a total return of +282. 5%, compared to -8. 1% for Helios Technologies, Inc. (HLIO). Over 10 years, the gap is even starker: CAT returned +1228% versus HLIO's +109. 8%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
04Which is safer — HLIO or CAT or EMR or ETN or HON?
By beta (market sensitivity over 5 years), Honeywell International Inc.
(HON) is the lower-risk stock at 0. 74β versus Helios Technologies, Inc. 's 1. 56β — meaning HLIO is approximately 110% more volatile than HON relative to the S&P 500. On balance sheet safety, Helios Technologies, Inc. (HLIO) carries a lower debt/equity ratio of 12% versus 2% for Honeywell International Inc. — giving it more financial flexibility in a downturn.
05Which is growing faster — HLIO or CAT or EMR or ETN or HON?
By revenue growth (latest reported year), Eaton Corporation plc (ETN) is pulling ahead at 10.
3% versus 3. 0% for Emerson Electric Co. (EMR). On earnings-per-share growth, the picture is similar: Helios Technologies, Inc. grew EPS 23. 9% year-over-year, compared to -15. 5% for Honeywell International Inc.. Over a 3-year CAGR, ETN leads at 9. 8% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
06Which has better profit margins — HLIO or CAT or EMR or ETN or HON?
Eaton Corporation plc (ETN) is the more profitable company, earning 14.
9% net margin versus 5. 8% for Helios Technologies, Inc. — meaning it keeps 14. 9% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: EMR leads at 19. 6% versus 7. 9% for HLIO. At the gross margin level — before operating expenses — EMR leads at 52. 8%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
07Is HLIO or CAT or EMR or ETN or HON more undervalued right now?
The PEG ratio (forward P/E divided by expected earnings growth rate) is the most precise measure of undervaluation relative to growth potential.
By this metric, Helios Technologies, Inc. (HLIO) is the more undervalued stock at a PEG of 1. 00x versus Honeywell International Inc. 's 11. 18x. A PEG below 1. 0 is traditionally considered the threshold for growth-adjusted undervaluation. On forward earnings alone, Honeywell International Inc. (HON) trades at 20. 5x forward P/E versus 38. 8x for Caterpillar Inc. — 18. 3x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for EMR: 14. 8% to $161. 92.
08Which pays a better dividend — HLIO or CAT or EMR or ETN or HON?
All stocks in this comparison pay dividends.
Honeywell International Inc. (HON) offers the highest yield at 2. 1%, versus 0. 5% for Helios Technologies, Inc. (HLIO).
09Is HLIO or CAT or EMR or ETN or HON better for a retirement portfolio?
For long-horizon retirement investors, Caterpillar Inc.
(CAT) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (0. 7% yield, +1228% 10Y return). Helios Technologies, Inc. (HLIO) carries a higher beta of 1. 56 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (CAT: +1228%, HLIO: +109. 8%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
10What are the main differences between HLIO and CAT and EMR and ETN and HON?
Both stocks operate in the Industrials sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform all of them.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.